- Pulmonary alveolar proteinosis (PAP) is a rare lung disorder characterized by the accumulation of surfactant within the alveoli, leading to impaired gas exchange and progressive respiratory dysfunction. The rising clinical recognition of PAP, along with improved diagnostic modalities, is driving demand for specialized drug therapies.
- The market is witnessing increasing demand due to growing awareness of PAP among healthcare professionals, the emergence of advanced therapies such as GM-CSF replacement and rituximab-based treatment for autoimmune PAP (aPAP), and ongoing research in targeted and supportive therapies, including whole lung lavage (WLL) and immunomodulatory approaches.
- North America dominates the PAP drug market with the largest revenue share of approximately 38.5% in 2025, driven by greater disease awareness, access to advanced diagnostics, and strong clinical research infrastructure, especially in the U.S. Key pharmaceutical and biotech companies are actively developing targeted biologics and enrolling patients in rare disease registries to improve disease management.
- Asia-Pacific is expected to be the fastest-growing region in the PAP drug market during the forecast period, owing to increasing healthcare investment, improved access to specialty care, and rising recognition of rare pulmonary conditions in countries like Japan, China, and South Korea.
- The autoimmune PAP segment is anticipated to dominate the market by disease type, accounting for approximately 62.3% of the global market share in 2025. This dominance is driven by its higher prevalence compared to congenital and secondary forms, as well as the availability of targeted therapies such as GM-CSF therapy and rituximab, which are demonstrating promising clinical outcomes
